Alimera Sciences, Inc. (ALIM) Major Shareholder Armistice Capital Master Fund Buys 20,000 Shares

Alimera Sciences, Inc. (NASDAQ:ALIM) major shareholder Armistice Capital Master Fund purchased 20,000 shares of Alimera Sciences stock in a transaction dated Tuesday, February 6th. The stock was acquired at an average price of $1.14 per share, for a total transaction of $22,800.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Alimera Sciences, Inc. (ALIM) remained flat at $$1.09 on Friday. The company’s stock had a trading volume of 256,305 shares, compared to its average volume of 164,086. The company has a market capitalization of $78.14, a PE ratio of -3.39 and a beta of 1.79. Alimera Sciences, Inc. has a 52-week low of $1.03 and a 52-week high of $1.72. The company has a debt-to-equity ratio of -0.71, a quick ratio of 4.65 and a current ratio of 4.84.

Several equities research analysts have recently weighed in on ALIM shares. ValuEngine upgraded Alimera Sciences from a “strong sell” rating to a “sell” rating in a report on Friday, October 20th. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Alimera Sciences in a report on Friday, October 27th. Cowen reiterated a “buy” rating on shares of Alimera Sciences in a report on Thursday, November 2nd. Finally, Zacks Investment Research downgraded Alimera Sciences from a “hold” rating to a “sell” rating in a report on Monday, November 27th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $3.38.

An institutional investor recently raised its position in Alimera Sciences stock. Stonepine Capital Management LLC boosted its position in shares of Alimera Sciences, Inc. (NASDAQ:ALIM) by 158.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 477,226 shares of the biopharmaceutical company’s stock after purchasing an additional 292,399 shares during the quarter. Alimera Sciences comprises about 0.4% of Stonepine Capital Management LLC’s portfolio, making the stock its 21st biggest position. Stonepine Capital Management LLC owned 0.69% of Alimera Sciences worth $644,000 at the end of the most recent reporting period. 41.77% of the stock is owned by institutional investors and hedge funds.

WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Insider Buying and Selling by Quarter for Alimera Sciences (NASDAQ:ALIM)

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with's FREE daily email newsletter.

Leave a Reply